Alnylam Pharmaceuticals, Inc. vs Global E Online Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.49 (market cap $29.60B), while Global E Online Ltd trades at $40.64 (market cap $6.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GLBE | |
|---|---|---|
Market Cap | $29.60B | $6.87B |
Sector | Health | Technology |
52-Week High | $491.22 | $42.32 |
52-Week Low | $205.48 | $27.54 |
Enterprise Value | $27.56B | $6.34B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
GLBE trades at $39.76, down 3.38% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with revenue up 39% year-over-year and an adjusted EBITDA margin expansion to 20.9%. Recent news highlights the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorization.
The outlook is positive, with 100% buy ratings from analysts and a consensus price target of $44.75 implying 12.5% upside. Key opportunities include robust revenue growth and margin expansion, while risks involve high valuation multiples and insider selling activity. The stock's trajectory hinges on continued execution of its global e-commerce enablement strategy.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →